Published in PLOS One on 2026-09-15, this study is presented as an attributed evidence briefing. The excerpts below are the original researchers’ words, reproduced under their Creative Commons Attribution licence. HealthSignal has selected the abstract and, where needed, opening background paragraphs; the complete methods, results, limitations and references remain in the linked paper.
Original authors: Victor Moses Musyoki, Marianne Mureithi, Annamari Heikinheimo, Elizabeth Maleche-Obimbo, Dishon Maina, Susan Musau, Ruth Maganga, Omu Anzala, Kariuki Njaanake
Source: PLOS One • DOI 10.1371/journal.pone.0358593
Read the complete primary study ↗ · Creative Commons Attribution licence
From the researchers
Abstract
Active tuberculosis (TB) infection can induce hyperglycaemia and insulin resistance, increasing the risk of type 2 diabetes mellitus and worsening TB disease severity. However, data on the dynamics of TB-associated hyperglycaemia and its effect on TB treatment outcomes among individuals not previously diabetic remain limited, particularly in high TB-burden settings. In this study, we aimed to investigate the prevalence and temporal patterns of TB-associated hyperglycaemia and its impact on disease presentation and TB treatment outcomes among a cohort of individuals not previously diabetic.
This was a five-month longitudinal prospective cohort study conducted at two urban specialized TB healthcare facilities in Kenya among adults aged >18 years with bacteriologically confirmed pulmonary TB (PTB). Known diabetes mellitus (DM) or prediabetic individuals were excluded during enrolment. Glycaemic status was assessed at baseline and months two and five using glycated haemoglobin (HbA1c) according to the American Diabetes Association guideline. Hyperglycaemia was defined as HbA1c ≥5.7% and categorized as normoglycaemia, persistent, transient, or incident hyperglycaemia based on longitudinal measurements. Socio-demographic and clinical data were collected using a structured questionnaire and analysed using SPSS version 26.0 and GraphPad Prism version 9.0. Longitudinal trends in HbA1c levels and the association of hyperglycaemia with DM-related symptoms, as well as TB treatment outcomes, were assessed using the Friedman test and the Generalized Estimating Equations (GEE), respectively.
We enrolled and followed 87 individuals newly diagnosed with PTB. Of these, 66 were tested for hyperglycaemia in month two after 7 died and 14 were lost to follow-up/transferred out (LTFU/TO), and 70 in month 5, after an additional death, 7 re-engagements, and 2 LTFU/TO were reported. At enrolment, the cohort was predominantly male (76%), not married (53%), and HIV-negative (84%), with a median age of 37 years (IQR 29–44). Prevalence of hyperglycaemia at baseline was 75% (95% Confidence Interval [CI] 65–83), with 45% of the individuals presenting as prediabetic and 30% as diabetic. At the month-two and month-five time points, the proportion of participants with prediabetes (pre-DM) increased from 24% (16/66) to 30% (21/70), while the prevalence of DM declined from 21% (14/66) to 9% (6/70). Across the time points, HbA1c levels varied significantly (p < 0.001). In GEE analysis, hyperglycaemic participants were more likely to experience classic symptoms of DM such as frequent micturition (adjusted Relative Risk [aRR] 1.76, 95% CI 1.12–2.77), increased thirst (aRR 2.37, 95% CI 1.38–4.05), unintentional weight loss (aRR 1.84, 95% CI 1.24–2.75), and blurred vision (aRR 1.95, 95% CI 1.20–3.18). After adjusting for age, BMI, HIV, alcohol use, and smoking, hyperglycaemia was independently associated with an increased risk of sputum positivity (aRR 4.22, 95% CI 2.09–8.52). Glycaemic variability was significantly associated with unfavourable TB treatment outcomes (p < 0.001).
Reading this evidence
Use the full paper to check the study design, participant selection, comparator and outcome definitions before drawing a practical conclusion. An association does not by itself show cause and effect. A reported performance measure needs its denominator and uncertainty. A finding from a particular facility, sample or time period should retain that scope when it is discussed elsewhere.
This briefing makes the source accessible within the wider research & evidence desk. It does not assess an individual patient or certify a product. When considering relevance to another health system, examine the original authors’ account of context and limitations, then seek local implementation evidence. The related reporting below provides other studies to read alongside this one; it is a topic connection, rather than a claim that their results are directly comparable.
© 2026 Victor Moses Musyoki, Marianne Mureithi, Annamari Heikinheimo, Elizabeth Maleche-Obimbo, Dishon Maina, Susan Musau, Ruth Maganga, Omu Anzala, Kariuki Njaanake. Excerpts reproduced under CC BY. Selection, formatting and contextual notes by HealthSignal. The researchers are the authors of the source study, not members of HealthSignal’s staff.
Explore connected evidence
- Evidence brief: Predictors of tuberculosis mortality among patients on treatment: A retrospective cohort study at a rural general hospital in Zambia
- Evidence brief: Time to treatment initiation in pregnant women with tuberculosis in Cape Town, South Africa
- Evidence brief: Empiric tuberculosis treatment and 12-month mortality among sputum GeneXpert-negative adults living with HIV in Uganda in the era of widespread antiretroviral therapy: A prospective cohort study
